"This is an incredibly exciting time for Parkinson's therapeutics," says Diane Stephenson, Vice President, Neurology, at the Critical Path for Parkinson's consortium.
We talk to Diane, who has spent 35 years working in the Parkinson's field, about the developments in research.
š buff.ly/YsAfc9R
